[
  {
    "ts": "2025-11-13T03:16:39+00:00",
    "headline": "Where Does Amgen Stand After 15% Surge and New Pipeline Approvals in 2025?",
    "summary": "Thinking about whether Amgen is a smart buy at today's prices? You are not alone, especially if you are trying to figure out if the current stock price reflects true value or hype. Amgen's share price has surged recently, up 5.1% in the last week and 15.0% over the past month, with year-to-date returns sitting at an impressive 29.7%. Part of this momentum can be traced to news around major pipeline drug approvals and fresh partnerships that have caught investor attention. Ongoing discussions...",
    "url": "https://finance.yahoo.com/news/where-does-amgen-stand-15-031639244.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "12e5726c-9122-3e5b-a5f0-b67628b7385d",
      "content": {
        "id": "12e5726c-9122-3e5b-a5f0-b67628b7385d",
        "contentType": "STORY",
        "title": "Where Does Amgen Stand After 15% Surge and New Pipeline Approvals in 2025?",
        "description": "",
        "summary": "Thinking about whether Amgen is a smart buy at today's prices? You are not alone, especially if you are trying to figure out if the current stock price reflects true value or hype. Amgen's share price has surged recently, up 5.1% in the last week and 15.0% over the past month, with year-to-date returns sitting at an impressive 29.7%. Part of this momentum can be traced to news around major pipeline drug approvals and fresh partnerships that have caught investor attention. Ongoing discussions...",
        "pubDate": "2025-11-13T03:16:39Z",
        "displayTime": "2025-11-13T03:16:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ACuIXYrNeojUXbAJFhnPIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B7CQJIEa.2c0sQ0XIU66pg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/where-does-amgen-stand-15-031639244.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/where-does-amgen-stand-15-031639244.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-13T14:45:38+00:00",
    "headline": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
    "summary": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
    "url": "https://finance.yahoo.com/news/nike-upgraded-dollar-tree-downgraded-144538422.html",
    "source": "The Fly",
    "provider": "yfinance",
    "raw": {
      "id": "8797ed93-cd75-34fe-b872-cf042d802372",
      "content": {
        "id": "8797ed93-cd75-34fe-b872-cf042d802372",
        "contentType": "STORY",
        "title": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
        "description": "",
        "summary": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
        "pubDate": "2025-11-13T14:45:38Z",
        "displayTime": "2025-11-13T14:45:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec",
          "originalWidth": 1200,
          "originalHeight": 628,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YHTvjvqtNAYBPYViMXYCow--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec.cf.webp",
              "width": 1200,
              "height": 628,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J3gfZRz3Jb2im4_aLYVn4g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Fly",
          "url": "https://thefly.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nike-upgraded-dollar-tree-downgraded-144538422.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nike-upgraded-dollar-tree-downgraded-144538422.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DASH"
            },
            {
              "symbol": "SSTI"
            },
            {
              "symbol": "CRCL"
            },
            {
              "symbol": "NKE"
            },
            {
              "symbol": "KRRO"
            },
            {
              "symbol": "DLTR"
            },
            {
              "symbol": "CRWV"
            },
            {
              "symbol": "COO"
            },
            {
              "symbol": "BKNG"
            },
            {
              "symbol": "AZO"
            },
            {
              "symbol": "LWAY"
            },
            {
              "symbol": "FAST"
            },
            {
              "symbol": "VITL"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "RKT"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-13T15:07:00+00:00",
    "headline": "2 Supercharged Dividend Stocks to Buy Now",
    "summary": "Innovative drugmakers often make for solid dividend stocks. These two companies are great examples.",
    "url": "https://www.fool.com/investing/2025/11/13/2-supercharged-dividend-stocks-to-buy-now/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "e90d66ae-3f39-3053-8162-cc8454cd50a6",
      "content": {
        "id": "e90d66ae-3f39-3053-8162-cc8454cd50a6",
        "contentType": "STORY",
        "title": "2 Supercharged Dividend Stocks to Buy Now",
        "description": "",
        "summary": "Innovative drugmakers often make for solid dividend stocks. These two companies are great examples.",
        "pubDate": "2025-11-13T15:07:00Z",
        "displayTime": "2025-11-13T15:07:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/993512d28d423028cab2d5363880c70e",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Doctor talking to patient.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XpOml5rc1w0CcogDaAM_iA--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/993512d28d423028cab2d5363880c70e.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZELoQPqpMjSGL0zahnb_9Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/993512d28d423028cab2d5363880c70e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/13/2-supercharged-dividend-stocks-to-buy-now/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-supercharged-dividend-stocks-buy-150700878.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "XBI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-13T17:09:43+00:00",
    "headline": "Jim Cramer Shows Confidence in Amgen",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently put under a microscope. Cramer showed quite a bullish sentiment toward the company’s stock, as he remarked: “If you want to venture beyond what we call the CPG, consumer packaged goods, world, I think you’d do very well with owning J&J or Amgen… Amgen’s […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-shows-confidence-amgen-170943108.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "7fca3d3b-5335-3ce6-9f2b-9a9ea2eeccfa",
      "content": {
        "id": "7fca3d3b-5335-3ce6-9f2b-9a9ea2eeccfa",
        "contentType": "STORY",
        "title": "Jim Cramer Shows Confidence in Amgen",
        "description": "",
        "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently put under a microscope. Cramer showed quite a bullish sentiment toward the company’s stock, as he remarked: “If you want to venture beyond what we call the CPG, consumer packaged goods, world, I think you’d do very well with owning J&J or Amgen… Amgen’s […]",
        "pubDate": "2025-11-13T17:09:43Z",
        "displayTime": "2025-11-13T17:09:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/5f241f83ea3e77a50a204217fc3a84bc",
          "originalWidth": 6000,
          "originalHeight": 4000,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZkD7SKPhnV0JAfwbIcdRzw--~B/aD00MDAwO3c9NjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/5f241f83ea3e77a50a204217fc3a84bc.cf.webp",
              "width": 6000,
              "height": 4000,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L4j5V2E1WUYhhZOm4mup9Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/5f241f83ea3e77a50a204217fc3a84bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-shows-confidence-amgen-170943108.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-shows-confidence-amgen-170943108.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-13T17:09:41+00:00",
    "headline": "Jim Cramer Notes Johnson & Johnson is “Really Bearing Down on High-Growth Pharma”",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently put under a microscope. Cramer said that “you’d do very well” owning the stock, as he stated: “If you want to venture beyond what we call the CPG, consumer packaged goods, world, I think you’d do very well with owning J&J or Amgen… […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-notes-johnson-johnson-170941713.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "7709e458-bedc-3e50-93c3-922691e0ca0e",
      "content": {
        "id": "7709e458-bedc-3e50-93c3-922691e0ca0e",
        "contentType": "STORY",
        "title": "Jim Cramer Notes Johnson & Johnson is “Really Bearing Down on High-Growth Pharma”",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently put under a microscope. Cramer said that “you’d do very well” owning the stock, as he stated: “If you want to venture beyond what we call the CPG, consumer packaged goods, world, I think you’d do very well with owning J&J or Amgen… […]",
        "pubDate": "2025-11-13T17:09:41Z",
        "displayTime": "2025-11-13T17:09:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/65a7a1fb9980055f966b10c1bd5e88d3",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V.cYaSHzzKzVHdGmA_7kFQ--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/65a7a1fb9980055f966b10c1bd5e88d3.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WQYQ_aVrFtQIDc0.PoEAUQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/65a7a1fb9980055f966b10c1bd5e88d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-notes-johnson-johnson-170941713.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-notes-johnson-johnson-170941713.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-13T22:36:27+00:00",
    "headline": "Why Amgen Stock Edged Past the Market on Thursday",
    "summary": "The pharmaceutical sector mainstay earned several positive mentions in the pundit sphere that day.",
    "url": "https://www.fool.com/investing/2025/11/13/why-amgen-stock-edged-past-the-market-on-thursday/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "696e9e3b-6a14-3976-aaf3-8d2a54de1397",
      "content": {
        "id": "696e9e3b-6a14-3976-aaf3-8d2a54de1397",
        "contentType": "STORY",
        "title": "Why Amgen Stock Edged Past the Market on Thursday",
        "description": "",
        "summary": "The pharmaceutical sector mainstay earned several positive mentions in the pundit sphere that day.",
        "pubDate": "2025-11-13T22:36:27Z",
        "displayTime": "2025-11-13T22:36:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/7e0efde0022124c2c9c5cfcb90cc3af5",
          "originalWidth": 1400,
          "originalHeight": 935,
          "caption": "Person checking the shelves of a pharmacy.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9pIxhNilYEHMQAZTnQW8xw--~B/aD05MzU7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/7e0efde0022124c2c9c5cfcb90cc3af5.cf.webp",
              "width": 1400,
              "height": 935,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.fM39KoYo_1O0VtISARLhg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/7e0efde0022124c2c9c5cfcb90cc3af5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/13/why-amgen-stock-edged-past-the-market-on-thursday/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-amgen-stock-edged-past-223627221.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]